Is RPHM undervalued or overvalued?
As of 2025-03-16, the Intrinsic Value of Reneo Pharmaceuticals Inc (RPHM) is -4.73 USD. This RPHM valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.82 USD, the upside of Reneo Pharmaceuticals Inc is -359.72%. This means that RPHM is overvalued by 359.72%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -4.73 - -4.73 | -4.73 | -359.72% |
| P/E | (14.09) - (21.78) | (15.08) | -928.5% |
| DDM - Stable | (8.17) - (24.94) | (16.55) | -1009.5% |
| DDM - Multi | (10.24) - (24.56) | (14.48) | -895.7% |
| Market Cap (mil) | 108.85 |
| Beta | -0.91 |
| Outstanding shares (mil) | 59.81 |
| Enterprise Value (mil) | 72.88 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.76% |
| Cost of Debt | 5.00% |
| WACC | 6.71% |